WE CAN HELP
Book a FREE consultation  
For a free consultation or assistance, please call 020 7730 6666

Browse by Category

Treating Alopecia Universalis with Xeljanz May Have Serious Side Effects

Tofacitinib citrate, a potential ‘miracle cure’ for hair loss from Alopecia Universalis, has hit the headlines in recent days after the product regrew the hair of a man with this severe condition which causes total baldness.  What we have been surprised to see here at The Belgravia Centre is the fact that none of the tabloids have reported on the risk of serious side effects that come with the use of this medication. These side effects include serious infections, tuberculosis and cancer. We examine the condition, this latest treatment and the studies surrounding the controversial drug.

Alopecia Universalis

There are three main forms of Alopecia with Alopecia Universalis being the rarest and the most severe kind. Caused by a genetic mutation of the chromosomes, this type of Alopecia is believed to be an autoimmune disorder. The condition can occur at any age and causes a total loss of hair on the scalp and body – including eyelashes and eyebrows – and can also damage nails. Whilst the hair does spontaneously grow back for some sufferers, even years after the onset of the condition, it cannot be predicted if or when this regrowth will occur.

There is currently no cure for Alopecia Universalis although a range of treatments have been explored, the most recent being the rheumatoid arthritis drug, Tofacitinib Citrate.

Tofacitinib Citrate (brand name, Xeljanz)

Arthritis Drug Used to Treat Hair Loss from Alopecia Universalis in Yale University Study

Made by Pfizer using the brand name Xeljanz, tofacitinib citrate is a Janus-associated kinase (JAK) inhibitor which works inside cells to disrupt intracellular activities inside the JAK pathways. These are paths within our cells that are used by some signalling proteins (cytokines) to help control immune and inflammatory responses. It is a small, film-coated pill which is taken orally.

Tofacitinib citrate was approved by the FDA for the treatment of moderate to severe cases of the autoimmune disease, rheumatoid arthritis, in adults in November 2012 but was dogged by complaints – firstly about the cost, then about the side effects.

Xeljanz is currently FDA-approved for the treatment of rheumatoid arthritis in the USA and has also received similar approvals for use in Argentina, Columbia, Kuwait, the United Arab Emirates, Russia and Switzerland. Japan have also approved tofacitinib citrate for this type of treatment in adults, however, there it goes by the brand name Jaquinus.

The drug – which is unavailable in the UK as it has not been granted a license by the Medicines and Healthcare products Regulatory Agency (MHRA) – had previously been used to successfully treat psoriasis in humans and to reverse lesser forms of alopecia in mice.

Results of the Yale University of Medicine Study Using Tofacitinib Citrate to Treat Alopecia Universalis

Scientists at America’s elite Yale University School of Medicine used the drug to treat a 25 year old patient who was referred to them for treatment of plaque psoriasis, a chronic immune-mediated skin disease, and the most common strain of psoriasis, which displays as inflamed, scaly skin.

However, his diagnosis of Alopecia Universalis – which had never been treated – was also noted by the medical team and they decided upon the tofacitinib citrate treatment in order to try to cure both conditions.

The unnamed patient was almost completely hairless when he started the treatment, with the only hair being within the psoriasis plaques on his scalp.

After taking an 8 month course of tofacitinib citrate which involved 10mg per day for two months, followed by 15mg of the drug per day for another three months, the treatment was deemed to be ‘mildly effective’ in treating the patient’s psoriasis, however, he saw amazing results in terms of hair regrowth.

The subject had completely regrown scalp hair, developed eyebrows, eyelashes and facial hair, armpit hair and other hair – the first hair the man had grown in seven years.

This Yale study is the first reported case of a successful, targeted treatment for the rare Alopecia Universalis condition.

The paper detailing the Yale study, “Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis” was written by Brett A. King, M.D., assistant professor of dermatology at Yale University School of Medicine and his dermatologist colleague, Brittany G. Craiglow, M.D.

Dr. King explained, “The results are exactly what we hoped for. This is a huge step forward in the treatment of patients with this condition. While it’s one case, we anticipated the successful treatment of this man based on our current understanding of the disease and the drug. We believe the same results will be duplicated in other patients, and we plan to try.”

He concluded, “There are no good options for long-term treatment of alopecia universalis. The best available science suggested this might work, and it has.”

Clinical Trials & the Reported Side Effects of Xeljanz

The study’s co-author, Dr. Craiglow, said, “By eight months there was full regrowth of hair. The patient has reported feeling no side effects, and we’ve seen no lab test abnormalities, either.”

The results from this study are extremely encouraging, however, further, wider-scale clinical trials are required in order to establish whether the use of tofacitinib citrate in combating Alopecia Universalis, as well as potentially other forms of hair loss, is safe. Particularly given the alarming side effects associated with the drug in connection with its treatment of rheumatoid arthritis in adults and various other conditions it has been tested for as a potential remedy, including Crohn’s disease, dry eyes, plaque psoriasis, renal transplant rejection,ulcerative colitis, and ankylosing spondylitis.

Many clinical trials of Xeljanz have been, and continue to be carried out in relation to the drug’s suitability and safety as a treatment for rheumatoid arthritis and psoriasis. Yale’s Dr. King has already submitted a proposal for a clinical trial involving a cream form of tofacitinib as a treatment for alopecia areata.

Phase III clinical trials for the study into the Long-Term Effectiveness And Safety Of Tofacitinib For The Treatment Of Rheumatoid Arthritis are still under way, with results expected in 2019. However, the Phase II trials tested Xeljanz in Rheumatoid Arthritis patients that had not responded to other therapy and found the most important side effects to be increased blood cholesterol levels  (12 to 25 mg/dl LDL and 8 to 10 mg/dl HDL at medium dosage levels) and neutropenia, a granulocyte disorder whose key symptom is a deficit of white blood cells which can then lead to an increased risk of infection.

Currently scheduled until November 2019, on-going clinical trials for the drug started in February 2007. In April 2011, four patients died after beginning clinical trials with tofacitinib citrate; Pfizer said that only one of the four deaths was related to tofacitinib.

In April 2013, Arthritis Research UK reported that the European Medicines Agency (the regulatory body in charge of drug approvals in the EU) had been advised not to approve tofacitinib for treatment of rheumatoid arthritis, saying ‘The European Medicines Agency (EMA) is unlikely to approve a new medication called tofacitinib citrate (brand name Xeljanz) for the treatment of adults with rheumatoid arthritis, after its Committee for Medicinal Products for Human Use (CHMP) failed to produce a positive recommendation… The committee also had “major concerns” about the medication’s safety with regard to serious infections, certain cancers, gastrointestinal perforations, liver damage and blood fat levels… Therefore, at that point in time, the CHMP was of the opinion that the benefits of Xeljanz did not outweigh its risks and recommended that it be refused marketing authorisation’.

Funmi Lampejo, Pharmacy Manager at The Belgravia Centre’s City of London clinic, explains, “Tofacitinib is an immunosuppresant. It works by damping down the immune system so that the progress and symptoms of diseases caused by the body’s own immune system attacking it can be slowed and relieved. The problem with that is that the body is not protected from opportunistic infections, and cancers are more likely to develop in the long term.”

“Essentially, they decided that the drug tofacitinib did not offer any added advantage over existing immunosuppressants, and had a worse adverse effect profile compared to drugs already on the market, particularly in patients with resistant rheumatoid arthritis. In addition, they were concerned about the incidences of serious side-effects such as cancers, infections and digestive tract problems. As the dose which may be effective for alopecia totalis and universalis has not yet been fully established, it may turn out that the adverse effect profile may improve. It is too early to speculate either way.”

The EMA’s Assessment report on Xeljanz from July 2013 highlighted a number of the European regulatory body’s ‘major concerns’ about the drug’s serious side effects and the Benefit-Risk balance.

Although the most common side effects of  Xeljanz in its usual role as rheumatoid arthritis medication, were found to be  upper respiratory tract infections, headaches, hypertension, diarrhoea and inflammation of the nasal passage (nasopharyngitis), the current Safety & Side Effects warnings on the product’s website and packaging clearly state that ‘Xeljanz may cause serious side effects’. These include:

  • Serious infections: ‘Some people have serious infections while taking Xeljanz , including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.’
  • Cancer and Immune System Problems: ‘Xeljanz may increase your risk of certain cancers by changing the way your immune system works.’
  • Tears (perforation) in the Stomach or Intestines: ‘Some people taking Xeljanz get tears in their stomach or intestine. This happens most often in people who also take non-steroidal, anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.’

The manufacturers also state that Xeljanz is not suitable for those with infections, liver, kidney or stomach problems including ulcers, and it should not by used by women who are, or are planning to become, pregnant. There are various other conditions where the drug is deemed unsuitable, such as if the patient has recently been vaccinated.

Alternative Treatments for Alopecia Universalis

Until the Tofacitinib Citrate study outlined above, the most effective treatment for Alopecia Universalis was thought to be topical Immunotherapy. This shocks the hair follicles into production by creating an allergic reaction on the affected areas of the skin. The treatment has a success rate of around 40% and needs to be ongoing for hair growth to continue, but reported side effects – most commonly including persistent dermatitis, generalized eczema and blistering – can be unpleasant.

Share this article

60 Comments

13th August, 2016 at 4:00 pm

shiny head

Hi. I stumbled across this site while researching alopecia universalis. I started losing my hair around 2008, andI lost the last of my hair around 2012. I did go through some treatments with my dermatologist with the tar shampoos, psoriasis (I don't have this) light treatment, Propecia, injections. but nothing worked. The only thing we didn't try was the allergic reaction. My nails are affected by this as well, as they are brittle I stopped treatment in 2013 Recently I went to a rheumatologist, due to my knuckles getting somewhat stiff, as another GP at my clinic thought that could be a cause of the AU, but was given a healthy green light. I suggested to my normal GP that the AU is stress related and he pretty much laughed. Blood work comes back with no abnormalities, though I feel t-levels could be a bit higher. Outside of some mild fatigue I generally feel ok and don't have much issue with energy. That said, this whole thing is wrecked me and tends to keep me down. Any suggestions as to someone I can see in the Chicagoland area that can help deal with this AU? Thanks for taking the time to read this.

15th August, 2016 at 9:42 am

Sarah Belgravia

Hi there, I'm afraid we can't recommend anyone to you but if you contact the NAAF (National Alopecia Areata Foundation) they should be able to help you. Very best of luck.

26th September, 2016 at 8:41 am

Anonymouse

I have a mild form of alopecia areata with a couple bald spots at the lower back of my head near my neck. They're easy to hide and aren't that much of a nuisance but I would still like to get it treated. I want to try out the topical cream form of tofacitnib but when reading the side effects, I notice the section which states that people that have taken corticosteroids are at a higher risk of stomach and intestinal tears. I've taken corticosteroids in the form of injections in my AA bald spots. Does that mean that I'm at a higher risk for the side effects of tofacitnib? How long should I, and everyone else with AA, wait for the tofacitnib clinical trial results?

28th September, 2016 at 12:29 pm

Daphne Janes

I also have AU and have had this for 15 years.. otherwise very healthy. Would love to know more about trials in the eastern side of the state.. if I can help, I would love to.. even though it may not help me. I have dealt with it this long and am okay with it. Thanks.. Daphne zjanes

5th October, 2016 at 1:45 pm

Sarah Belgravia

Hi Daphne, the only trials we are aware of are taking place in New York and are not currently recruiting but if you contact the university directly they may be able to help you further.

5th October, 2016 at 1:47 pm

Sarah Belgravia

Hi Anonymouse, we cannot provide or speculate about medical advice in relation to this as tofacitinib is still in the very early stages of testing in both oral and topical forms. It is likely to be 2020 at the earliest that we see significant progress with this drug but we will post updates as to its progress here on the Belgravia hair loss blog.

18th October, 2016 at 4:18 am

Rudy Saenz

Good evening. My son developed alopecia areata. He is 14 years old. It has turned his life upside down now being a freshman in high school. I want to help my son. I would like to see if they would allow him to be in the clinical trials for the Xeljanz. Please consider him. He is healthy except for the Alopecia Areat and some mild psoriasis. Thank you for your help.

18th October, 2016 at 9:16 am

Sarah Belgravia

Hi Rudy, Unfortunately we are not involved in these trials so cannot help your son. The best thing to do if you are interested is to contact the University who is running the trials directly. However, we believe they are not accepting new volunteers at present. If your son has alopecia areata - patchy hair loss on his scalp rather than baldness from alopecia totalis or alopecia universalis - then treatment is available from 16 years of age.

23rd October, 2016 at 6:03 am

Abhi

I m suffering from AU since my birth. My nails of hands n legs r also wrinkled or dekay. Plz suggest me d best result oriented treatment. M 19yr young.

24th October, 2016 at 4:27 pm

Sarah Belgravia

Hi Abhi, there is currently no truly effective treatment for alopecia universalis. There are some promising drugs being trialled at the moment so there is hope that a treatment will be discovered in the next few years. You can read more about these on the Alopecia section of the Belgravia blog. However, at present there are no treatments for the hair loss or dermatological effects of this condition. Sorry we do not have better news for you.

Comment on this article

* required field

Will not be published

Online Consultation

Submit an instant online consultation so that one of Belgravia’s hair loss specialists can diagnose your condition and recommend an effective course of treatment, wherever you live.

08 Dec

Hair Loss Can Make Men Look Up to Eight Years Older Than They Are

A new survey has revealed that when it comes to physical factors that influence how old you appear, hair loss is the most ageing. Thinning hair tops ageing factors According to the findings, being overweight or having a moustache added an average of two years to a man’s perceived age. Yet, although greying hair added seven years, obvious Male […]

Read full article »
07 Dec

Success Story Alert! New Male Hair Loss Treatment Entry

A new entry has just been added to Belgravia’s Male Hair Loss Treatment Success Stories gallery. This patient is happy with his regrowth in general; his photoscans show visible improvements on both top and crown areas. Find out what he had to say and see his regrowth results close up, or find out more about treating Male Pattern […]

Read full article »
07 Dec

‘Does Men’s Hair Tonic Help Fight Hair Loss?’

Name: Will Question: Please help! See picture – is this hair tonic good for my hair? Fighting hair loss Answer: Hi, Will. No, hair tonic won’t help with hair loss I’m afraid. It is purely a styling product. Hair tonic was popular in the 1950s and 60s and is starting to become fashionable again for men’s hair styling. It […]

Read full article »